



NEWS RELEASE

## Repligen to Present at Stifel Nicolaus Healthcare Conference 2012

2012-08-29

- Thursday, September 6, 10:20 a.m. EDT -

WALTHAM, Mass.--(BUSINESS WIRE)-- Repligen Corporation (NASDAQ:RGEN) today announced that Walter C. Herlihy, Ph.D., President and Chief Executive Officer, will be presenting at the upcoming Stifel Nicolaus Healthcare Conference in Boston. Dr. Herlihy will provide a corporate update and discuss the Company's recent decision to focus corporate strategy on the growth of its bioprocessing business. The Repligen presentation is scheduled for Thursday, September 6, 2012 at 10:20 a.m. EDT.

A live webcast and subsequent archived replay of the presentation will be available through the Investors section of Repligen's corporate website at [www.repligen.com](http://www.repligen.com). To access the live webcast, please log on through the Company's website approximately 15 minutes prior to the presentation.

### About Repligen Corporation

Repligen Corporation is a life sciences company focused on the development, production and commercialization of products used in the process of manufacturing biological drugs. Our bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. We are a leading manufacturer of Protein A, a critical reagent used to manufacture monoclonal antibody-based therapeutics. We also supply several growth factor products used to increase cell culture productivity in biomanufacturing. In the burgeoning area of disposable biomanufacturing technologies, we have developed and market a series of OPUS™ (Open Platform User Specified) single-use chromatography columns used in the biologics purification process. In addition to our core bioprocessing business, we have a portfolio of clinical-stage partnering assets, including two central nervous system orphan drug candidates and a pancreatic imaging agent in Phase 3 development. Repligen's corporate

headquarters are located in Waltham, MA, USA; we have an additional manufacturing facility in Lund, Sweden. For more information, please visit our website at [www.repligen.com](http://www.repligen.com).

This press release may contain forward-looking statements within the meaning of the federal securities laws. Investors are cautioned that statements in this press release which are not strictly historical statements including, without limitation, statements identified by words like "believe," "expect," "may," "will," "should," "seek," or "could" and similar expressions, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, risks discussed from time to time in our filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update forward-looking statements, except as required by law.

Repligen Corporation  
Sondra S. Newman, 781-419-1881  
Director Investor Relations  
[snewman@repligen.com](mailto:snewman@repligen.com)

Source: Repligen Corporation